share_log

Altamira Therapeutics | 424B4: Prospectus

Altamira Therapeutics | 424B4: Prospectus

Altamira Therapeutics | 424B4：募資說明書
美股sec公告 ·  04/17 16:25
Moomoo AI 已提取核心訊息
Altamira Therapeutics Ltd., a Bermuda-based biopharmaceutical company, has announced a prospectus relating to the resale of up to 2,000,000 common shares by selling shareholder Lincoln Park Capital Fund, LLC (LPC). The shares have a par value of USD 0.002 each and are traded on The Nasdaq Capital Market under the symbol 'CYTO'. The resale is part of a Purchase Agreement dated December 5, 2022, which allows Altamira to issue and sell shares to LPC at its discretion, subject to certain conditions. Altamira will not sell any securities under this prospectus and will not receive proceeds from LPC's resale of shares. However, the company may receive up to $8,814,200 from the sale of Purchase Shares to LPC over time. LPC, considered an 'underwriter', may sell the shares at varying prices. The closing price of Altamira's common shares on Nasdaq as of April 5, 2024, was $1.975 per share. The company, identified as a 'foreign private issuer', is subject to reduced reporting requirements and has highlighted the investment risks in its common shares. The prospectus date is April 17, 2024.
Altamira Therapeutics Ltd., a Bermuda-based biopharmaceutical company, has announced a prospectus relating to the resale of up to 2,000,000 common shares by selling shareholder Lincoln Park Capital Fund, LLC (LPC). The shares have a par value of USD 0.002 each and are traded on The Nasdaq Capital Market under the symbol 'CYTO'. The resale is part of a Purchase Agreement dated December 5, 2022, which allows Altamira to issue and sell shares to LPC at its discretion, subject to certain conditions. Altamira will not sell any securities under this prospectus and will not receive proceeds from LPC's resale of shares. However, the company may receive up to $8,814,200 from the sale of Purchase Shares to LPC over time. LPC, considered an 'underwriter', may sell the shares at varying prices. The closing price of Altamira's common shares on Nasdaq as of April 5, 2024, was $1.975 per share. The company, identified as a 'foreign private issuer', is subject to reduced reporting requirements and has highlighted the investment risks in its common shares. The prospectus date is April 17, 2024.
總部位於百慕大的生物製藥公司Altamira Therapeutics Ltd. 宣佈了一份招股說明書，內容涉及出售股東林肯公園資本基金有限責任公司（LPC）轉售多達200萬股普通股。這些股票的面值爲每股0.002美元，在納斯達克資本市場上交易，股票代碼爲 “CYTO”。此次轉售是2022年12月5日收購協議的一部分，該協議允許阿爾塔米拉在某些條件下自行向LPC發行和出售股票。阿爾塔米拉不會根據本招股說明書出售任何證券，也不會從LPC轉售股票中獲得收益。但是，隨着時間的推移，該公司可能通過向LPC出售購買股份獲得高達8,814,200美元的收入。被視爲 “承銷商” 的LPC可能會以不同的價格出售股票。截至2024年4月5日，阿爾塔米拉在納斯達克的普通股的收盤價爲每股1.975美元。該公司被認定爲 “外國私人發行人”，其報告要求有所降低，並強調了其普通股的投資風險。招股說明書日期爲2024年4月17日。
總部位於百慕大的生物製藥公司Altamira Therapeutics Ltd. 宣佈了一份招股說明書，內容涉及出售股東林肯公園資本基金有限責任公司（LPC）轉售多達200萬股普通股。這些股票的面值爲每股0.002美元，在納斯達克資本市場上交易，股票代碼爲 “CYTO”。此次轉售是2022年12月5日收購協議的一部分，該協議允許阿爾塔米拉在某些條件下自行向LPC發行和出售股票。阿爾塔米拉不會根據本招股說明書出售任何證券，也不會從LPC轉售股票中獲得收益。但是，隨着時間的推移，該公司可能通過向LPC出售購買股份獲得高達8,814,200美元的收入。被視爲 “承銷商” 的LPC可能會以不同的價格出售股票。截至2024年4月5日，阿爾塔米拉在納斯達克的普通股的收盤價爲每股1.975美元。該公司被認定爲 “外國私人發行人”，其報告要求有所降低，並強調了其普通股的投資風險。招股說明書日期爲2024年4月17日。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息